A phase II evaluation of weekly docetaxel (NSC #628503) in the treatment of recurrent or persistent endometrial carcinoma

Trial Profile

A phase II evaluation of weekly docetaxel (NSC #628503) in the treatment of recurrent or persistent endometrial carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2014

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jan 2014 Planned number of patients changed from 19 to 51, as reported by ClinicalTrials.gov record
    • 15 Jan 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record
    • 06 Mar 2008 Status changed from completed to in progress, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top